Expression of β-integrin family members in children with T-cell acute lymphoblastic leukemia
KONG Qing-Lin, AN Xi-Zhou, GUAN Xian-Min, MA Yi-Mei, LI Peng-Fei, LIANG Shao-Yan, HU Yan-Ni, CUI Ying-Hui, YU Jie
Department of Hematology, Children's Hospital of Chongqing Medical University/Ministry of Education Key Laboratory of Child Development and Disorders/Chongqing Key Laboratory of Pediatrics/China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing, China
Abstract Objective To study the expression of β-integrin family members in children with T-cell acute lymphoblastic leukemia (T-ALL) and their significance. Methods Quantitative real-time PCR analyses were performed to assess the expression levels of β-integrin family members in bone marrow samples from 22 children with newly-diagnosed T-ALL and 21 controls (16 children with non-malignant hematologic disease and 5 healthy donors with bone marrow transplantation). Jurkat cells were treated with integrin inhibitor arginine-glycine-aspartate (Arg-Gly-Asp, RGD) peptide. The cell viability and apoptosis rate were determined by CCK8 assay and flow cytometry respectively. Results The mRNA levels of integrins β2, β3, and β5 were significantly lower in children with T-ALL than in controls (P < 0.05). In T-ALL patients, high integrin β3 expression was associated with lower white blood cell counts (< 100×109/L), minimal residual disease (MRD) positivity, and day 33 bone marrow negative remission (P < 0.05). In T-ALL patients, higher integrin β5 expression was associated with relapse of T-ALL (P < 0.05). Based on survival curve analysis, higher integrin β3 expression was related to lower event-free survival and overall survival rates. RGD peptide treatment inhibited the proliferation of Jurkat cells and increased their apoptosis rate (P < 0.05). Conclusions β-Integrin may play a role in the occurrence and development of T-ALL by affecting cell proliferation and apoptosis. The expression of integrin β5 is closely related to the risk of relapse of T-ALL. The expression of integrin β3 is closely related the treatment response and prognosis of T-ALL.
KONG Qing-Lin,AN Xi-Zhou,GUAN Xian-Min et al. Expression of β-integrin family members in children with T-cell acute lymphoblastic leukemia[J]. CJCP, 2017, 19(6): 620-626.
KONG Qing-Lin,AN Xi-Zhou,GUAN Xian-Min et al. Expression of β-integrin family members in children with T-cell acute lymphoblastic leukemia[J]. CJCP, 2017, 19(6): 620-626.
Durinck K, Goossens S, Peirs S, et al. Novel biological insights in T-cell acute lymphoblastic leukemia[J]. Exp Haematol, 2015, 43(8):625-639.
[2]
Cox CV, Martin HM, Keams PR, et al. Characterization of a progenitor cell population in childhood T-cell acute lymphoblastic leukemia[J]. Blood, 2007, 109(2):674-682.
[3]
Goldberg JM, Silverman LB, Levy DE, et al. Childhood T-cell acute lymphoblastic leukemia:the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience[J]. J Clin Oncol, 2003, 21(19):3616-3622.
[4]
Desgrosellier JS, Cheresh DA. Integrins in cancer:biological implications and therapeutic opportunities[J]. Nat Rev Cancer, 2010, 10(1):9-22.
Kapp TG, Rechenmacher F, Sobahi TR, et al. Integrin modulators:a patent review[J]. Expert Opin Ther Pat, 2013, 23(10):1273-1295.
[7]
Lambert AW, Ozturk S, Thiagalingam S. Integrin signaling in mammary epithelial cells and breast cancer[J]. ISRN Oncol, 2012, 2012:493283.
[8]
Akkari L, Gocheva V, Kester JC, et al. Distinct functions of macrophage-derived and cancer cell-derived cathepsin Z combine to promote tumor malignancy via interactions with the extracellular matrix[J]. Genes Dev, 2014, 28(19):2134-2150.
Kapp TG, Rechenmacher F, Sobahi TR, et al. Integrin modulators:a patent review[J]. Expert Opin Ther Pat, 2013, 23(10):1273-1295.
[13]
Roth P, Silginer M, Goodman SL, et al. Integrin control of the transforming growth factor-β pathway in glioblastoma[J]. Brain, 2013, 136(Pt 2):564-576.
